Building better biological AI models requires more than simply generating more data. Four initiatives launched or expanded in ...

FDA approved the first plasmid DNA-based immunotherapy in October, granting accelerated approval to Inovio’s Voceryq ...

Genetic studies continue to strengthen the case for targeting microglia in Alzheimer’s disease. The harder task is ...

Caspian is developing an oral menin inhibitor to regenerate patients’ own pancreatic beta cells, with plans to begin testing ...

For more than a decade, it has been clear that U.S. clinical trials are too slow, too costly, and too far removed from the ...

Only about 5% of rare diseases have an approved therapy, and this is unlikely to change without novel development processes.

A single trading day offers limited evidence, but Friday’s sharp divergence between tech and large-cap biopharma stocks suggests the latter could ...

Washington spends enormous energy scrutinizing the policy positions of FDA commissioner nominees. But does it pay enough attention to whether they can ...

The political action committees of the 10 largest drugmakers by 2025 global pharmaceutical sales, along with PhRMA and BIO, directed nearly all their ...

Gilde’s Impact Council as a multi-stakeholder diligence engine — Former regulators, HTA leaders, payers, clinicians, and ...

FDA has at least eleven PDUFA dates on its November calendar, 10 of which are for new products. First up is PD-1 x VEGF ...

The growing trend of co-development, co-commercialization deals may get cut in its prime if the COINS Act is finalized as ...